Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Pek

Tianjin 510080

0 studies enrolling now · 1 studies all time

What they study most

Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Studies at this site

• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early